vemurafenib,cobimetinib,temsirolimus,atezolizumab,trastuzumab,sunitinib,larotrectinib,pertuzumab,palbociclib,entrectinib,regorafenib,tucatinib,nivolumab,futibatinib,abemaciclib,pembrolizumab,talazoparib,olaparib,ipilimumab
bms,bayer,astrazeneca,pfizer,eli lilly,seagen,merck,otsuka,roche
['mbc', 'breast', 'tapur', 'brca', 'talazo', 'solid tumor']
talazoparib (tala) in patients (pts) with solid tumors with brca1/2 mutation (mut): results from the targeted agent and profiling utilization registry (tapur) study. #mbc #asco23 #clinicaltrials #cancerresearch #metastaticbreastcancer #denovombc 